Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Vaccine increases disease-free survival for follicular lymphoma patients

01.06.2011
Landmark study of personalized therapy may lead to a 'flood of new agents'

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.

"The study continues to show that the vaccine increases the usual time until relapse for follicular lymphoma by about 14 months. That's significant because most cancer drugs are approved on the basis of extending survival only a few months," said Larry Kwak, M.D., Ph.D., corresponding author of the study. Kwak, who invented the vaccine while at the National Cancer Institute, chairs M. D. Anderson's Department of Lymphoma and Myeloma.

"These results have the potential to usher in a new age of cancer vaccines," he said. "I believe a whole flood of agents will soon begin to show positive results."

The multi-center study is the first successful phase III trial of a lymphoma vaccine and one of the first of a personalized cancer therapy agent. Initial results were presented in part at the Plenary Session of the American Society of Clinical Oncology (ASCO) Annual Meeting in 2009.

Tumors' proteins used to tune immune system attack

Kwak, who has devoted 20 years to investigating the science of cancer vaccines, specifically a personalized therapy for follicular lymphoma, was named in 2010 as one of Time magazine's 100 most influential people.

"This vaccine is a true example of a homegrown agent we've taken from bench to bedside," he said. "We discovered it in the laboratory, and we've taken it all the way through the clinical trial process. Now its approval as a commercial drug may be imminent."

To make the vaccine, unique proteins from each patient's tumor are isolated and combined with a delivery agent and a growth factor. This mixture then is injected back into the patient. Earlier studies showed this approach induces anti-tumor immune responses with few side effects in most lymphoma patients.

"It's the ultimate in personalized therapy," Kwak said. "Even if two patients have the same type of lymphoma, their tumors will still have different proteins."

According to the National Cancer Institute, non-Hodgkin's lymphoma is one of the most common cancers in the United States. More than 74,000 people were diagnosed with the disease in 2010. Follicular lymphoma accounts for 22 percent of non-Hodgkin lymphomas worldwide.

"Survival of follicular lymphoma patients has improved with newer types of chemotherapy, but advanced-stage disease still is considered incurable," Kwak said. "Although we usually can get the disease into remission, it comes back in almost all patients without further treatment."

Some patients appear to have even stronger response

The 234 patients in this trial first were treated with a chemotherapy combination known as PACE. Of these patients, 117 went into complete remission or had a complete response for at least six months, and they received either the vaccine or a placebo. During a median follow-up period of 55.6 months, median time to relapse for the 76 vaccinated patients was 44.2 months, compared with 30.6 months for the 41 who received placebo.

However, an unplanned subgroup analysis showed that patients with a certain biological marker had an even more profound response, extending disease-free survival time from 28.7 months to 52.9 months. While those results need to be confirmed in randomized studies, they suggest the potential for further targeting the vaccine.

"This huge difference points the way toward specific patients who may be likely to respond even more dramatically to the vaccine," Kwak said. "It also helps focus priorities moving forward. For instance, the Food and Drug Administration (FDA) might expedite commercial development of the drug because they know it works so well for certain patients."

What's next?

These findings may be applicable to other types of cancers, as well as a broader range of lymphoma patients. In addition, Kwak said a next-generation lymphoma vaccine his team has been working on should enter clinical testing sometime within the next year.

The National Cancer Institute advanced the vaccine by sponsoring its first randomized phase III clinical trial with the intention of handing the trial off to a corporate partner. BioVest International prevailed in a competitive process to collaborate with the NCI and took over the trial in 2004. BioVest is developing the vaccine under the brand name BioVaxID™. The company is moving forward to secure FDA approval of the vaccine. This trial was supported by National Cancer Institute and Biovest International, Inc.

Co-lead authors were Sattva Neelapu, M.D., principal investigator at MD Anderson, and Stephen Schuster, M.D., Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA. Other research team members included Elise Chong, B.A., Abramson Cancer Center of the University of Pennsylvania, Philadelphia; Donald Berry, Ph.D., MD Anderson Department of Biostatistics; Barry Gause, M.D., John Janik, M.D., Elaine Jaffe, M.D., Craig W. Reynolds, Ph.D., Center for Cancer Research, National Cancer Institute, National Institutes of Health; Franco Muggia, M.D., NYU Cancer Institute, New York University School of Medicine; Jon Gockerman, M.D., Duke University Comprehensive Cancer Center; Jane Winter, M.D., Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Christopher Flowers, M.D., Emory University Winship Cancer Institute; Daniel Nikcevich, M.D., Ph.D., SMDC Cancer Center and Duluth CCOP; Eduardo Sotomayor, M.D., H. Lee Moffitt Cancer Center and Research Institute; Dean McGaughey, M.D., Virginia Oncology Associates; and Carlos Santos, Ph.D., Mihaela Popa, M.D., Ph.D. and Amy McCord, Ph.D., Biovest International, Inc.

Schuster, Neelapu, Janik, Muggia, Gockerman, Winter and Flowers received research support from Biovest International, Inc. Santos, Popa and McCord are employees of Biovest International, Inc. Flowers, Berry and Kwak received consulting fees from Biovest International, Inc. Gause, Santos and Popa own Biovest stock.

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For seven of the past nine years, including 2010, MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.

Scott Merville | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Bare bones: Making bones transparent

27.04.2017 | Life Sciences

Study offers new theoretical approach to describing non-equilibrium phase transitions

27.04.2017 | Physics and Astronomy

From volcano's slope, NASA instrument looks sky high and to the future

27.04.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>